Literature DB >> 10636626

Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: the potential importance of bacterial translocation.

F M Brunkhorst1, A L Clark, Z F Forycki, S D Anker.   

Abstract

AIMS: Exposure to bacterial endotoxin, perhaps due to bowel congestion or ischaemia and altered gut permeability, may result in immune activation that is characteristic for patients with severe heart failure. It is known that blood procalcitonin rises in response to bacterial endotoxin exposure.
METHODS: We measured procalcitonin in a group of 29 patients with acute cardiogenic shock and no sign of infection (all without bacteraemia) and 26 with septic shock. Blood was analysed for procalcitonin, interleukin-6, tumour necrosis factor-alpha (TNF-alpha), c-reactive protein (CRP) and neopterin. Patients were managed conventionally in an intensive care unit with no further experimental procedures.
RESULTS: Three cardiogenic (10%) and seven septic shock patients (27%) survived. Most patients with acute heart failure surviving 12 h or more (18 of 20) developed a pyrexia (738.0 degrees C) of unknown origin in the absence of positive cultures, with a rise in procalcitonin (1.4+/-0.8 to 48.0+/-16.2 ng/ml, P<0.001), CRP (76.5+/-16.4 to 154.7+/-22.9 mg/l, P<0.001) and neopterin (20.7+/-3.5 to 41.2+/-6.7 nmol/l, P<0.001). Patients with septic shock had higher initial levels of cytokines, and higher peak levels. Those with heart failure surviving (n=3) and those dying in the first 12 h (n=9) had no rise in cytokine levels. The patients with high procalcitonin had a higher temperature (38.9+/-0.3 vs. 37.3+/-0.23 degrees C, P<0.05), TNF-alpha (43.95+/-9.64 vs. 16.43+/-4.33 pg/ml; P<0.005) and CRP (146.1+/-18.4 vs. 68.2+/-39.6 mg/ml, P<0.005). Peak procalcitonin levels correlated with peak temperature (r=0.74, P<0.001).
CONCLUSION: Cardiogenic shock causes a pyrexia of unknown origin in patients surviving for 12 h and that is associated with a rise in procalcitonin levels. This lends support to the hypothesis that patients with cardiogenic shock may be being exposed to bacterial endotoxin at a time when bowel wall congestion and or ischaemia is likely to be present.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10636626     DOI: 10.1016/s0167-5273(99)00118-7

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  26 in total

1.  Cardiogenic shock--an inflammatory disease.

Authors:  Gottfried Heinz
Journal:  Wien Klin Wochenschr       Date:  2006-07       Impact factor: 1.704

Review 2.  Procalcitonin in acute cardiac patients.

Authors:  Claudio Picariello; Chiara Lazzeri; Serafina Valente; Marco Chiostri; Gian Franco Gensini
Journal:  Intern Emerg Med       Date:  2010-09-29       Impact factor: 3.397

3.  Procalcitonin and acute coronary syndromes: a new biomarker for an old disease.

Authors:  Luigi M Biasucci; Gina Biasillo; Antonella Stefanelli
Journal:  Intern Emerg Med       Date:  2009-07-29       Impact factor: 3.397

4.  Bacteraemia prediction in emergency medical admissions: role of C reactive protein.

Authors:  D H Wyllie; I C J W Bowler; T E A Peto
Journal:  J Clin Pathol       Date:  2005-04       Impact factor: 3.411

5.  Diagnostic value of lipopolysaccharide-binding protein and procalcitonin for sepsis diagnosis in forensic pathology.

Authors:  Marc Augsburger; Katia Iglesias; Daniel Bardy; Patrice Mangin; Cristian Palmiere
Journal:  Int J Legal Med       Date:  2012-10-13       Impact factor: 2.686

6.  Soluble ST2 levels in patients with cardiogenic and septic shock are not predictors of mortality.

Authors:  Jiri Parenica; Jan Malaska; Jiri Jarkovsky; Jolana Lipkova; Milan Dastych; Katerina Helanova; Jiri Litzman; Josef Tomandl; Simona Littnerova; Jana Sevcikova; Roman Gal; Pavel Sevcik; Jindrich Spinar; Monika Pavkova Goldbergova
Journal:  Exp Clin Cardiol       Date:  2012

Review 7.  Cardiogenic Shock: Failure of Oxygen Delivery and Oxygen Utilization.

Authors:  Hoong Sern Lim
Journal:  Clin Cardiol       Date:  2016-08-10       Impact factor: 2.882

8.  Usefulness of procalcitonin for diagnosing complicating sepsis in patients with cardiogenic shock.

Authors:  Alexander Geppert; Angela Steiner; Georg Delle-Karth; Gottfried Heinz; Kurt Huber
Journal:  Intensive Care Med       Date:  2003-06-20       Impact factor: 17.440

9.  Procalcitonin in patients with acute coronary syndromes and cardiogenic shock submitted to percutaneous coronary intervention.

Authors:  Claudio Picariello; Chiara Lazzeri; Marco Chiostri; Gianfranco Gensini; Serafina Valente
Journal:  Intern Emerg Med       Date:  2009-07-08       Impact factor: 3.397

Review 10.  Biomarkers: a definite plus in pneumonia.

Authors:  Hanssa Summah; Jie-Ming Qu
Journal:  Mediators Inflamm       Date:  2009       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.